IPL (Intense Pulsed Light) and BBL (BroadBand Light) are both broadband light devices that treat pigment, redness, and photoaging without surgery or downtime. They are often described interchangeably, and in many clinics the terms are used as synonyms. They are not the same thing.
BBL is a specific platform manufactured by Sciton (Palo Alto, CA) that sits in the IPL category but uses a different hardware architecture — dual flashlamps, square-pulse energy delivery, interchangeable Smart Filters — that changes how energy reaches the skin. BBL HEROic is the latest generation, adding continuous-motion delivery with AI-driven pulse adjustment.
Both platforms work through selective photothermolysis: light energy is absorbed by target chromophores (melanin for pigment, hemoglobin for vascular lesions, water for tissue heating) and converted to heat that damages the target while sparing surrounding tissue. But the delivery differences matter — for treatment speed, consistency, skin-type safety, and the range of concerns each can address.
This article breaks down how each device works, what the evidence supports (and what it does not), who is and is not a candidate, and how to evaluate whether the premium of a BBL HEROic treatment is justified for a specific patient.
How IPL works
Traditional IPL uses a single high-output flashlamp to generate a broad spectrum of noncoherent polychromatic light, typically in the 500–1,200nm range depending on the device. Multiple wavelengths are emitted simultaneously, which is why IPL can address pigment and vascular concerns in the same session — but also why it is less precise than single-wavelength lasers.
The clinical workflow is "stamp and move": the provider places the handpiece against the skin, fires a pulse, moves to the next spot, and repeats. Energy output can vary between pulses, and the flashlamp degrades over its lifespan, producing less consistent delivery as the lamp ages.
IPL is effective for:
- Sun spots, freckles, and superficial pigmentation
- Redness from rosacea and broken capillaries (telangiectasias)
- Mild skin texture improvement through collagen stimulation
- Brighter, more even skin tone
IPL is not effective for:
- Deep wrinkles or significant skin laxity
- Acne scars
- Fitzpatrick IV–VI skin at standard settings (too much melanin in the epidermis absorbs energy indiscriminately, causing burns and post-inflammatory hyperpigmentation)
A standard IPL protocol calls for 3–5 sessions spaced 3–4 weeks apart, with 1–2 maintenance sessions per year. Face treatments take 10–30 minutes. Downtime is minimal: redness and a mild sunburn sensation for a few hours, pigmented spots darken and then flake off over 7–14 days.
How BBL HEROic is different
BBL was developed by Sciton starting in 2004. The current generation, BBL HEROic, differs from traditional IPL in several hardware-level ways:
Dual flashlamps. Two lamps instead of one provide more consistent energy delivery from the first pulse to the last, with less lamp degradation over time. The output is roughly 3x higher than traditional IPL devices.
Square-pulse technology. Energy is distributed evenly across the entire pulse duration. Traditional IPL pulses can have peaks and valleys in energy output, meaning some portions of the pulse deliver more energy than intended and others deliver less. Square-pulse delivery aims to eliminate this variability.
9 interchangeable Smart Filters in one handpiece. Traditional IPL devices typically require a different handpiece for each wavelength range. BBL uses a single handpiece with swappable filters (515nm, 560nm, 590nm, 615nm, 640nm, 695nm, and others) that can be changed during treatment. This allows the provider to treat pigment with a 515nm filter, switch to a 560nm filter for deeper vascular concerns, and adjust for skin type — all in the same session, without changing hardware.
Continuous motion with Intelligent Control. BBL HERO (High Energy Rapid Output) introduced continuous-motion delivery: the provider glides the handpiece across the skin rather than stamping individual pulses. BBL HEROic adds Sciton's proprietary Intelligent Control (IC) with Autodynamic Pulsing — a sensor-driven system that automatically modulates pulse rate based on handpiece speed and skin position, ensuring consistent pulse overlap and even coverage. The result is treatment up to 4x faster than traditional IPL — a full face in minutes, full body in the time it previously took for a small area.
Integrated cooling. CoolComfort technology provides contact cooling that reduces surface temperature during treatment. This is relevant for patient comfort and for safety in medium skin tones, where excess heat increases PIH risk.
FDA clearance
The Sciton Joule multi-platform system, which houses the BBL module, received FDA 510(k) clearance under K101916 on March 18, 2011. The BBL module is cleared for: benign pigmented lesions, dyschromia, age and sun spots, vascular lesions, rosacea, cherry angiomas, telangiectasias, mild-to-moderate inflammatory acne vulgaris, and hair removal. Cleared for skin types I–V.
Additional related clearances include K213350 (April 2022, JOULE platform updates) and K213761 (July 2022, JOULE diVa Laser Device additions).
The FDA clearance is for treating specific conditions. "Forever Young BBL" — the brand name for a protocol of regular maintenance treatments — is not an FDA-cleared indication. The gene-expression claims associated with this protocol come from independent research, not from an FDA-cleared endpoint.
The Stanford gene expression study
The most widely cited research behind BBL is a pilot study published in the Journal of Investigative Dermatology in 2013, led by Dr. Anne Lynn S. Chang at Stanford University School of Medicine.
The study design: skin biopsies from three groups — young people who had never had BBL, older people with photoaged skin who had never had BBL, and older people with photoaged skin after three BBL treatments over three months. RNA expression analysis of approximately 22,000 genes was performed on all samples.
Of 2,265 genes whose expression was altered in aged skin, 1,293 transcripts were "rejuvenated" — their expression patterns reverted to more closely resemble those of younger skin cells. The rejuvenated genes included those associated with longevity, translation, RNA processing, and other fundamental cellular processes, not just collagen.
The study concluded that "regulators of aging can be altered in human skin using BBL technology to provide a functional change, rather than just a cosmetic mimic of youthful appearance."
The limitations are significant. The sample size was small — 5 older women and 5 younger women. The study was funded by a research grant from Sciton. The clinical significance of "1,293 rejuvenated genes" at the visible, patient-perceivable level has not been established in large, controlled trials. And no comparable study has been published for traditional IPL devices, so it is unclear whether the gene expression effect is specific to BBL's hardware or is a property of broadband light treatment more broadly.
A follow-up retrospective study by Dr. Patrick Bitter Jr. showed maintained clinical improvement up to 7 years with regular BBL treatments, but this was a retrospective case series, not a randomized controlled trial.
What the BBL HERO + Moxi combination study found
A 2024 study by Hennessey in the Journal of Clinical and Aesthetic Dermatology examined a single combined session of BBL HERO and Moxi (a 1,927nm non-ablative fractional laser made by Sciton) for solar lentigines in 9 patients aged 29–64 (Fitzpatrick II–III). All patients showed marked pigmentation reduction, with improvement maintained up to 19.7 months in one patient after a single treatment. No adverse events were reported. No funding was provided for this study.
This is relevant because it reflects the emerging clinical pattern of combining BBL with fractional laser for comprehensive pigment and texture treatment — but it is a small study, and the results reflect combination therapy, not BBL alone.
Fitzpatrick skin type safety
This is where the two platforms diverge most meaningfully for patient selection.
Fitzpatrick I–III (fair to medium skin): Both IPL and BBL are safe and effective. Lower epidermal melanin means less risk of post-inflammatory hyperpigmentation or burns. Standard settings can be used. This is the population most IPL and BBL clinical data come from.
Fitzpatrick IV (olive to light brown skin): IPL becomes riskier. The higher melanin content in the epidermis absorbs light energy indiscriminately, increasing the risk of burns, PIH, and hypopigmentation. Treatment is possible but requires experienced providers, modified settings (longer wavelengths, lower fluences), and test spots. BBL's adjustable filters, advanced cooling, and square-pulse delivery provide additional safety margins — but the risk is not zero. BBL's FDA clearance extends to skin type V.
Fitzpatrick V–VI (brown to dark brown/black skin): Neither device is safe at standard settings. The risk of PIH, hypopigmentation, and scarring is significant. Neither IPL nor BBL is FDA-cleared for skin type VI. Patients in this group who want pigment or redness treatment should be directed to devices with longer wavelengths that bypass epidermal melanin — Nd:YAG-based platforms, for example.
Neither device should be used on tanned skin of any Fitzpatrick type. The increased melanin from tanning raises the same PIH and burn risk regardless of baseline skin color.
Cost and treatment comparison
| Factor | Traditional IPL | BBL HEROic |
|---|---|---|
| Cost per face session | $300–$600 | $450–$800 |
| Cost per body session | Varies | $650–$1,200 |
| Sessions typically needed | 3–5 | 3–4 |
| Session spacing | 3–4 weeks | 3–4 weeks |
| Face treatment time | 10–30 minutes | Significantly faster (up to 4x) |
| Downtime | Hours (redness); pigment darkens 7–14 days | Hours (redness); reportedly less than IPL |
| Maintenance | 1–2 sessions per year | 2–4 sessions per year (Forever Young protocol) |
The per-session cost of BBL HEROic is roughly 30–50% higher than traditional IPL. Whether that premium is justified depends on what the patient is treating. For straightforward sun spots on Fitzpatrick II skin, traditional IPL from a well-maintained device is effective and less expensive. For rosacea with diffuse redness, Fitzpatrick III skin, or patients who want faster treatment with potentially more consistent results, BBL's hardware advantages may be worth the cost difference.
The Forever Young BBL protocol
"Forever Young BBL" is Sciton's branded protocol for ongoing maintenance treatment — typically 2–4 BBL sessions per year, indefinitely. The premise, drawn from the Stanford gene expression study and Bitter's follow-up retrospective data, is that regular broadband light treatments maintain gene expression patterns associated with younger skin and prevent photoaging from accumulating.
The evidence chain is: a small pilot study (n=10) showing 1,293 rejuvenated genes, a retrospective case series showing maintained improvement up to 7 years with regular treatments, and Sciton's marketing. The protocol is not an FDA-cleared indication, and no large, randomized controlled trial has validated the anti-aging claim. Patients considering a long-term Forever Young commitment should understand that the evidence is suggestive but not conclusive, and the cost accumulates over years.
Before and after treatment
Before (both IPL and BBL):
- Avoid sun exposure and tanning for 2–4 weeks prior
- Stop retinoids, exfoliants, and active skincare 3–5 days before
- Avoid aspirin and blood thinners for 1 week (if cleared by prescribing physician)
- Arrive with clean, makeup-free skin
After — what to expect day by day:
- Day 0: Redness and warmth (like a mild sunburn) for a few hours. Mild swelling around eyes and cheeks possible.
- Days 1–3: Pigmented spots darken and look more prominent — this is expected, not a complication. Continue gentle moisturizer.
- Days 5–7: Darkened spots begin to flake off. Do not pick or exfoliate.
- Days 7–14: Skin settles. Cleared pigment becomes visible. Full result per session apparent at 2–4 weeks.
- Ongoing: Wear SPF 30+ daily. Avoid direct sun exposure for at least 2 weeks. Do not use harsh exfoliants or active ingredients for one week post-treatment.
Combination treatment: BBL HEROic + Moxi
A growing number of clinics offer BBL HEROic and Moxi (Sciton's 1,927nm non-ablative fractional laser) as a combined session. The logic: BBL addresses color — pigment, redness, and dyschromia — while Moxi addresses texture, tone, and collagen remodeling through fractional laser channels. The 2024 Hennessey study showed that a single combined session produced marked pigmentation reduction maintained for up to 19.7 months.
This combination is increasingly common in clinical practice and may be the right approach for patients who want both color correction and texture improvement in fewer total sessions. It is not necessary for everyone — patients with isolated pigment or isolated redness may not need the fractional component — but it reflects the direction of broadband light treatment in 2026.
What neither device can do
Neither IPL nor BBL is a substitute for:
- Ablative or fractional laser resurfacing for deep wrinkles, acne scars, or significant texture irregularities
- Surgical intervention for skin laxity
- Any treatment that permanently stops aging or prevents sun damage from recurring
- Safe treatment of Fitzpatrick VI skin at standard settings
Both platforms improve pigment and redness. Both stimulate mild collagen production. Both require ongoing maintenance. Neither produces the dramatic textural or tightening results that some clinic marketing implies.
Sources
- Chang ALS, Bitter PH Jr, et al. "Rejuvenation of Gene Expression Pattern of Aged Human Skin by Broadband Light Treatment: A Pilot Study." J Invest Dermatol. 2013;133:394-402. https://pmc.ncbi.nlm.nih.gov/articles/PMC3547222/
- Hennessey E. "A Novel Combination of BroadBand Light (BBL HERO) and Nonablative Fractionated 1,927nm (MOXI) Laser for Addressing Solar Lentigines." J Clin Aesthet Dermatol. 2024;17(9-10):s1-s36. https://pmc.ncbi.nlm.nih.gov/articles/PMC11460752/
- FDA 510(k) Premarket Notification K101916 — Sciton Joule Multi-Platform System. https://www.accessdata.fda.gov/cdrh_docs/pdf10/K101916.pdf
- Bitter PH Jr. "Noninvasive Rejuvenation of Photodamaged Skin Using Serial, Full-face Intense Pulsed Light Treatments." Dermatologic Surgery. 2000;26:835-842.
- FDA. "Aesthetic Cosmetic Devices." https://www.fda.gov/medical-devices/products-and-medical-procedures/aesthetic-cosmetic-devices
- AAD. "Intense pulsed light (IPL) therapy." https://www.aad.org/public/everyday-care-skin-health-secrets
